Meeting
2017 ASCO Annual Meeting
Vitamin K epoxide reductase complex subunit 1 (VKORC1): A pharmacogenomic predictor of response and survival in patients (pts) on triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-Cet) for initially unresectable liver metastases from colorectal cancer (uLM-CRC) (EU trial OPTILIV).
Authors
Francis Levi
Cancer Chronotherapy Unit, Warwick Medical School, Coventry, United Kingdom
Francis Levi , Raphael Saffroy , Abdoulaye Karaboue , Christophe Desterke , Valerie Boige , Mohamed Hebbar , Denis Michel Smith , Mohamed Bouchahda , Pasquale Innominato , Julien Taieb , Carlos Carvalho , Rosine Guimbaud , C. N. J. Focan , Michel Ducreux , Rene Adam , Antoinette Lemoine
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Pharmacology
Clinical Trial Registration Number
NCT00852228
Citation
J Clin Oncol 35, 2017 (suppl; abstr 2569)
DOI
10.1200/JCO.2017.35.15_suppl.2569
Abstract #
2569
Poster Bd #
61
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Four-year survival in patients (pts) undergoing liver surgery after neoadjuvant triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-CET) for previously treated and unresectable liver metastases from kras wt colorectal cancer (LM-CRC) (European trial OPTILIV, NCT00852228).
First Author: Francis Levi
Poster
2013 Gastrointestinal Cancers Symposium
Final results of first European phase II trial of intravenous cetuximab (Cet) and hepatic artery infusion of irinotecan, 5-fluorouracil and oxaliplatin in patients (pts) with unresectable liver metastases from wt KRAS colo-rectal cancer (LM-CRC) after systemic treatment failure (OPTILIV, NCT00852228).
First Author: Francis Levi
First Author: Francis Levi
Poster
2020 ASCO Virtual Scientific Program
Cetuximab/irinotecan/5-FU +/-oxaliplatin or FOLFOXIRI +/- bevacizumab in patients with colorectal cancer and nonresectable liver metastases (AIO CELIM2-study).
First Author: Gunnar Folprecht